Skip to content

Pharmacy

CVS closes purchase of Target pharmacies, clinics

CVS closes purchase of Target pharmacies, clinics

CVS Health has completed its $1.9 billion acquisition of Target Corp.’s pharmacy and retail health clinic business. The companies said Wednesday that Target’s 1,672 pharmacies in 47 states will be branded as CVS/pharmacy and operated under a store-within-a-store format.

Sanofi, Boehringer Ingelheim mull business swap

Sanofi, Boehringer Ingelheim mull business swap

Sanofi and Boehringer Ingelheim are in talks to swap their animal health and consumer health care businesses, respectively. The companies said Tuesday that the proposed transaction would involve an exchange of Sanofi’s Merial animal health business (“Merial”), valued at €11.4 billion ($12.

Allergan rolls out IBS drug Viberzi

Allergan rolls out IBS drug Viberzi

Allergan plc has released Viberzi (eluxadoline), a treatment for irritable bowel syndrome with diarrhea (IBS-D), to U.S. pharmacies. The company said Monday that Viberzi, a twice-daily oral medication, relieves the core symptoms of IBS-D: recurrent diarrhea and abdominal pain.

Endo granted extended U.S. rights for Voltaren Gel

Endo granted extended U.S. rights for Voltaren Gel

Endo International plc has received an extension of its exclusive U.S. marketing rights for Voltaren Gel (diclofenac sodium topical gel 1%), a nonsteriodal anti-inflammatory drug (NSAID). Endo said Monday that it also was granted extended U.S.

Horizon adds gout drug with Crealta acquisition

Horizon adds gout drug with Crealta acquisition

Horizon Pharma plc plans to acquire Crealta Holdings LLC for $510 million in cash. Horizon said the deal will bring the company Krystexxa (pegloticase), the first and only Food and Drug Administration-approved drug for chronic refractory gout.

Takeda’s Ninlaro becomes available in U.S.

Takeda’s Ninlaro becomes available in U.S.

Takeda Pharmaceutical Co. has released Ninlaro capsules (ixazomib), a blood cancer medication, in the United States. Takeda said Friday that Ninlaro is the first and only oral proteasome inhibitor.

NCPA urges more scrutiny of generic drug pricing

NCPA urges more scrutiny of generic drug pricing

In tandem with a congressional hearing, the National Community Pharmacists Association called on lawmakers to take a closer look at recent generic drug price hikes and their impact on patients and community pharmacists.

Amneal starts rollout of lidocaine product line

Amneal starts rollout of lidocaine product line

Amneal Pharmaceuticals LLC has begun shipping lidocaine 5% ointment to lead off the launch of a new lidocaine product line. Amneal said late Tuesday that its lidocaine 5% ointment is available in a 35.44-g tube with child-resistant cap and in a 50-g jar.

Camber launches generic version of Prozac

Camber launches generic version of Prozac

Camber Pharmaceuticals has released fluoxetine capsules, an antidepressant, and losartan potassium, a hypertension medication. Camber said Tuesday that its fluoxetine capsules are available in strengths of 10 mg, 20 mg, 40 mg in both 30 and 100-count bottles.

Affordable Care Act encounters new headwinds

Affordable Care Act encounters new headwinds

UnitedHealth Group Inc. may pull out of Affordable Care Act health insurance exchanges in 2017 after losing what it said were hundreds of millions of dollars on policies sold under the law.

Health care spending outpaces economy

Health care spending outpaces economy

Health care spending in the United States last year exceeded $3 trillion as five years of slow growth was replaced by the Affordable Care Act’s expansion of Medicaid and private health insurance coverage. Prescription drug prices accelerated as well.

Pfizer-Allergan deal is expected to stand

Pfizer-Allergan deal is expected to stand

Despite widespread criticism over the issue of tax inversions, legal experts say that current regulatory restrictions in the United States are unlikely to block the $160 billion merger deal announced by U.S. pharmaceutical giant Pfizer and Ireland-based drug manufacturer Allergan Inc.

Heritage releases Calan generic

Heritage releases Calan generic

Heritage Pharmaceuticals Inc. has rolled verapamil 40-mg immediate-release tablets, a calcium channel blocker medication. Heritage said that its verapamil product is a generic version of Pfizer Inc.’s Calan, indicated for the treatment of angina, arrhythmias and hypertension.